Absenteeism Among Employees Treated for Depression
- 1 July 1999
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Occupational and Environmental Medicine
- Vol. 41 (7), 605-611
- https://doi.org/10.1097/00043764-199907000-00009
Abstract
Depression-related costs include a relatively large share of indirect costs. We describe the impact of antidepressant treatment on absenteeism among workers diagnosed and treated for depression. Monthly absenteeism counts from employers were summed in the 6 months before and after the initiation of antidepressant therapy in 630 workers treated for depression with a tricyclic antidepressant or a selective serotonin reuptake inhibitor (fluoxetine, sertraline, paroxetine). Monthly mean absenteeism was compared using pairwise t tests. Absenteeism increased before antidepressant initiation and decreased after the treatment began for all antidepressant cohorts. Absenteeism in the selective serotonin reuptake inhibitor cohorts decreased at similar rates for 4 months but was higher in the paroxetine cohort in months five and six after the treatment initiation. Our data suggest that alternative treatments for depression may have differential impact on indirect costs, but further research is warranted.Keywords
This publication has 12 references indexed in Scilit:
- Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.Journal of Affective Disorders, 1998
- Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of DepressionPharmacoEconomics, 1998
- Serotonin Reuptake Inhibitor WithdrawalJournal of Clinical Psychopharmacology, 1996
- Antidepressant Withdrawal SyndromeCNS Drugs, 1996
- Antidepressant Pharmacotherapy: Economic Evaluation of Fluoxetine, Paroxetine and Sertraline in a Health Maintenance OrganizationJournal of International Medical Research, 1995
- A Meta-Analysis of Fluoxetine Outcome in the Treatment of DepressionThe Journal of Nervous and Mental Disease, 1994
- Lifetime and 12-Month Prevalence of DSM-III-R Psychiatric Disorders in the United StatesArchives of General Psychiatry, 1994
- Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability.BMJ, 1993
- Comorbid anxious signs and symptoms in major depressionInternational Clinical Psychopharmacology, 1993
- Treatments of Depression and the Functional Capacity to WorkArchives of General Psychiatry, 1992